Cardiff Oncology (CRDF) Competitors $2.81 +0.06 (+2.18%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$2.82 +0.00 (+0.18%) As of 05/16/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDF vs. VIR, AVXL, NUVB, QURE, IMNM, AVBP, TRVI, PHAR, DAWN, and DNTHShould you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), Nuvation Bio (NUVB), uniQure (QURE), Immunome (IMNM), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), Pharming Group (PHAR), Day One Biopharmaceuticals (DAWN), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. Cardiff Oncology vs. Vir Biotechnology Anavex Life Sciences Nuvation Bio uniQure Immunome ArriVent BioPharma Trevi Therapeutics Pharming Group Day One Biopharmaceuticals Dianthus Therapeutics Cardiff Oncology (NASDAQ:CRDF) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk. Does the MarketBeat Community favor CRDF or VIR? Vir Biotechnology received 15 more outperform votes than Cardiff Oncology when rated by MarketBeat users. However, 65.15% of users gave Cardiff Oncology an outperform vote while only 56.86% of users gave Vir Biotechnology an outperform vote. CompanyUnderperformOutperformCardiff OncologyOutperform Votes4365.15% Underperform Votes2334.85% Vir BiotechnologyOutperform Votes5856.86% Underperform Votes4443.14% Do analysts rate CRDF or VIR? Cardiff Oncology presently has a consensus target price of $12.00, suggesting a potential upside of 327.05%. Vir Biotechnology has a consensus target price of $32.86, suggesting a potential upside of 614.29%. Given Vir Biotechnology's higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiff Oncology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Vir Biotechnology 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Do insiders & institutionals believe in CRDF or VIR? 16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 7.7% of Cardiff Oncology shares are owned by company insiders. Comparatively, 15.6% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media favor CRDF or VIR? In the previous week, Vir Biotechnology had 8 more articles in the media than Cardiff Oncology. MarketBeat recorded 12 mentions for Vir Biotechnology and 4 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 1.48 beat Vir Biotechnology's score of 0.56 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Is CRDF or VIR more profitable? Vir Biotechnology has a net margin of -678.40% compared to Cardiff Oncology's net margin of -6,238.17%. Vir Biotechnology's return on equity of -36.71% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Cardiff Oncology-6,238.17% -73.97% -60.40% Vir Biotechnology -678.40%-36.71%-31.00% Which has more volatility and risk, CRDF or VIR? Cardiff Oncology has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Which has stronger earnings and valuation, CRDF or VIR? Cardiff Oncology has higher earnings, but lower revenue than Vir Biotechnology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiff Oncology$587K318.46-$41.44M-$0.92-3.05Vir Biotechnology$14.30M44.46-$615.06M-$4.22-1.09 SummaryVir Biotechnology beats Cardiff Oncology on 11 of the 18 factors compared between the two stocks. Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDF vs. The Competition Export to ExcelMetricCardiff OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$186.94M$2.88B$5.36B$8.52BDividend YieldN/A1.96%4.95%4.12%P/E Ratio-2.9930.7326.9120.00Price / Sales318.46405.60389.58119.42Price / CashN/A168.6838.2534.62Price / Book1.803.066.764.60Net Income-$41.44M-$72.35M$3.23B$248.70M7 Day Performance5.64%3.92%4.87%5.15%1 Month Performance-1.40%8.36%9.91%13.68%1 Year Performance-22.59%-28.72%14.89%6.77% Cardiff Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDFCardiff Oncology1.5872 of 5 stars$2.81+2.2%$12.00+327.0%-24.9%$186.94M$587,000.00-2.9920Gap UpVIRVir Biotechnology2.7673 of 5 stars$5.30+4.1%$32.86+519.9%-53.7%$731.74M$14.30M-1.35580News CoverageAVXLAnavex Life Sciences3.9374 of 5 stars$8.55+3.6%$44.00+414.6%+84.9%$729.93MN/A-15.5540News CoverageEarnings ReportAnalyst RevisionNUVBNuvation Bio3.5796 of 5 stars$2.15+2.6%$7.83+265.2%-33.9%$726.47M$7.87M-0.9960Positive NewsAnalyst ForecastGap UpQUREuniQure2.3004 of 5 stars$13.15+2.8%$37.82+187.6%+170.2%$720.30M$27.12M-2.65500Earnings ReportAnalyst RevisionGap UpIMNMImmunome2.6546 of 5 stars$7.94+6.4%$25.33+219.1%-44.0%$690.88M$9.04M-0.9840News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionAVBPArriVent BioPharma1.027 of 5 stars$19.99-0.8%$39.00+95.1%-3.9%$680.56MN/A-7.7840Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionTRVITrevi Therapeutics3.4623 of 5 stars$6.70+1.5%$17.56+162.1%+128.9%$669.28MN/A-15.2320News CoveragePositive NewsPHARPharming Group1.8551 of 5 stars$9.81-2.2%$30.00+206.0%-1.2%$667.04M$297.20M-37.71280Gap DownDAWNDay One Biopharmaceuticals2.971 of 5 stars$6.58+2.0%$30.57+364.6%-61.0%$666.96M$161.92M-6.3960DNTHDianthus Therapeutics1.286 of 5 stars$20.08+2.5%$54.33+170.6%-25.0%$645.09M$6.24M-8.0380Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap Up Related Companies and Tools Related Companies VIR Competitors AVXL Competitors NUVB Competitors QURE Competitors IMNM Competitors AVBP Competitors TRVI Competitors PHAR Competitors DAWN Competitors DNTH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRDF) was last updated on 5/17/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
